A phase 1/2 dose escalation study of TRU-015 in subjects with relapsed or refractory B cell non-Hodgkin's lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs TRU 015 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Wyeth
- 04 Apr 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 27 Dec 2007 Status changed from initiated to recruiting.
- 03 Sep 2007 New trial record.